+

US6114376A - Methods for using macrocyclic lactone compounds as multidrug resistance reversing agents in tumor and other cells - Google Patents

Methods for using macrocyclic lactone compounds as multidrug resistance reversing agents in tumor and other cells Download PDF

Info

Publication number
US6114376A
US6114376A US09/067,677 US6767798A US6114376A US 6114376 A US6114376 A US 6114376A US 6767798 A US6767798 A US 6767798A US 6114376 A US6114376 A US 6114376A
Authority
US
United States
Prior art keywords
cells
ivm
macrocyclic lactone
cem
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US09/067,677
Other languages
English (en)
Inventor
Roger K. Prichard
Jean-François Pouliot
Elias Georges
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
McGill University
International Business Machines Corp
Original Assignee
McGill University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US09/067,677 priority Critical patent/US6114376A/en
Application filed by McGill University filed Critical McGill University
Priority to PCT/IB1998/000750 priority patent/WO1998048813A1/fr
Priority to AU70736/98A priority patent/AU744406B2/en
Priority to EP98917538A priority patent/EP0979089B1/fr
Priority to DE69832375T priority patent/DE69832375T2/de
Priority to CA002289086A priority patent/CA2289086C/fr
Priority to ES98917538T priority patent/ES2252832T3/es
Assigned to INTERNATIONAL BUSINESS MACHINES CORPORATION reassignment INTERNATIONAL BUSINESS MACHINES CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BAYARDO, ROBERTO J.
Priority to DK98917538T priority patent/DK0979089T3/da
Priority to NZ500429A priority patent/NZ500429A/en
Priority to AT98917538T priority patent/ATE309805T1/de
Assigned to MCGILL UNIVERSITY reassignment MCGILL UNIVERSITY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GEORGES, ELIAS, POULIOT, JEAN-FRANCOIS, PRICHARD, ROGER K.
Publication of US6114376A publication Critical patent/US6114376A/en
Application granted granted Critical
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • This invention relates generally to novel methods for enhancing the biological activity of chemotherapeutic agents. More specifically, the invention pertains to unique methods for increasing the toxicity of cytostatic hydrophobic chemotherapeutic agents using multidrug resistant reversing agents in which the multidrug resistant reversing agents are macrocyclic lactone compounds.
  • Pgp is a member of the ABC (ATP binding cassette) superfamily of membrane transporters that includes the multidrug resistance associated protein MRP (Cole et al., Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells, Cancer Res. 54: 5902-5910, 1994), the cystic fibrosis transmembrane conductance regulator (CFTR) (Riordan et al., Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines, Nature 316: 817-819, 1985) and several bacterial periplasmic membrane proteins (Higgins, ABC transporters: from microorganisms to man, Annu. Rev. Cell Biol. 8: 67-113, 1992).
  • MRP multidrug resistance associated protein
  • CTR cystic fibrosis transmembrane conductance regulator
  • Pgp has been shown to cause multidrug resistance (MDR) in tumor cells, its function in normal tissues is less certain.
  • Pgp gene family in rodents and humans consists of three classes (I, II, and III) and two classes (I and III), respectively.
  • classes I and II have been shown to cause MDR, class III of both rodents and humans does not.
  • class I Pgp is involved in drug transport in normal tissues while class III Pgp mediates phosphatidyl-choline transport (Smit et al., Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease, Cell 75: 451-462, 1993) and may be "a flipase" (Ruetz et al., Phosphatidyl-choline translocase--a physiological role for the mdr2 gene, Cell 77: 1071-1081, 1994).
  • CEM tumoral lymphoid
  • LL-F28249 compounds have been widely used for treatment of nematode and arthropod parasites.
  • the highly active LL-F28249 family of compounds are natural endectocidal agents isolated from the fermentation broth of Streptomyces cyaneogriseus subsp. noncyanogenus.
  • U.S. Pat. No. 5,106,994 and its continuation U.S. Pat. No. 5,169,956 describe the preparation of the major and minor components, LL-F28249 ⁇ - ⁇ .
  • the LL-F28249 family of compounds further includes, but is not limited to, the semisynthetic 23-oxo derivatives and 23-imino derivatives of LL-F28249 ⁇ - ⁇ which are shown in U.S. Pat. No. 4,916,154.
  • Moxidectin chemically known as 23-(O-methyloxime)-LL-F28249 ⁇ , is a particularly potent 23-imino derivative.
  • Other examples of LL-F28249 derivatives include, but are not limited to, 23-(semicarbazone)-LL-F28249 ⁇ and 23-(thiosemicarbazone)-LL-F28249 ⁇ .
  • milbemycins also known as the B-41 series of antibiotics
  • B-41 series of antibiotics are naturally occurring macrocyclic lactones isolated from the microorganism, Streptomyces hygroscopicus subsp. aureolacrimosus.
  • U.S. Pat. No. 3,950,360 shows the preparation of the macrolide antibiotics milbemycin.sub. ⁇ 1- ⁇ 10, milbemycin.sub. ⁇ 1- ⁇ 3 etc.
  • These compounds are also commonly referred to as milbemycin A, milbemycin B, milbemycin D and the like, or antibiotic B-41A1, antibiotic B-41A3, etc.
  • avermectins also known as the C-076 family of compounds, are naturally occurring macrocyclic lactones produced by the soil actinomycete microorganism, Streptomyces avermitilis.
  • U.S. Pat. No. 4,310,519 discloses the isolation and preparation of the major components A 1a (e.cf avermectin A 1a ), A 2a , B 1a and B 2a , and the minor components A 1b (e.c., avermectin A 1b ), A 2b , B 1b and B 2b .
  • the C-076 family additionally embraces the semisynthetic derivatives such as the 22,23-dihydroavermectins described in U.S. Pat. No. 4,199,569.
  • the semisynthetic derivatives include, but are not limited to, ivermectin, abamectin, doramectin, eprinomectin and the like.
  • IVM Ivermectin
  • 22,23-dihydroavermectin B 1 or 22,23-dihydro C-076 B 1 is shown, for example, to be an anthelmintic of great efficiency and low toxicity (Campbell, Ivermectin and Abamectin, Springer, N.Y., 1989).
  • IVM has been successfully used orally, by subcutaneous injection or transdermal uptake to cure nematode infections in animals and has also been used in humans to treat several types of infections, such as onchocerciaisis (river blindness).
  • IVM binds with high affinity to a glutamate-gated chloride channel in nematodes (Cully et al., Cloning of an avermectin-sensitive glutamate-gated chloride channel from Caenorhabditis elegans, Nature 371: 707-711, 1994).
  • IVM is highly selective for the invertebrate chloride channel but binds with only low affinity to the ⁇ -aminobutyric acid-gated (GABA-gated) chloride channel in vertebrate brain (Cully et al., Solubilization and characterization of a high affinity ivermectin binding site from Caenorhabditis elegans, Mol. Pharmacol. 40: 326-332, 1991; Schaeffer et al., Avermectin binding in Caenorhabditis elegans. A two-state model for the avermectin binding site, Biochem. Pharmacol. 38: 2329-2338, 1989).
  • GABA-gated ⁇ -aminobutyric acid-gated
  • IVM invertebrate glutamate-gated chloride channel
  • the binding of IVM to the invertebrate glutamate-gated chloride channel keeps the chloride channel open and prevents membrane depolarization, leading to the paralysis of the nematode.
  • the low host toxicity of IVM is due to both the low affinity towards the host receptor and the compartmentalization of the receptor in the brain.
  • IVM which is very hydrophobic, does not effectively cross the blood-brain barrier at low concentrations (Chiu et al., Absorption, tissue distribution, and excression of tritium-labeled ivermectin in cattle, sheep and rat, J. Agric. Food. Chem. 38: 2072-2078, 1990).
  • ivermectin may act as a substrate and an inhibitor of Pgp but the study failed to adequately explain the ivermectin toxicity found in SDZ-PSC 833-treated mice (Didier et al., The abamectin derivative ivermectin is a potent P-glycoprotein inhibitor, Anti-Cancer Drugs, 7: 745-751, 1996).
  • macrocyclic lactone endectocides are surprisingly powerful multidrug resistance reversing agents which are capable of enhancing the potency of certain chemotherapeutic agents against resistant tumors and other related cells.
  • a new LL-F28249 derivative has also been found to unexpectedly possess potent multidrug resistance reversing properties which is useful for overcoming drug resistance in tumor cells and other diseases.
  • FIGS. 1A and 1B show ivermectin (IVM) and vinblastine (VLB) accumulation and efflux by cancer cells.
  • Drug-sensitive (CEM) and drug-resistant (CEM/VLB 1 .0) cells are incubated at 37° C. in ⁇ -MEM for 0-60 minutes in the presence 200 nM [ 3 H]-IVM (FIG. 1A) or [ 3 H]-vinblastine (FIG. 1B) alone or in the presence of 10 mM sodium azide.
  • the cells are then washed and the efflux is carried out at 37° C. in ⁇ -MEM for times varying from 0-30 minutes.
  • the accumulation values represent the mean ⁇ SD of three experiments.
  • FIGS. 2A and 2B show the competitive inhibition of ivermectin and vinblastine uptake.
  • Drug-sensitive (CEM) and drug-resistant (CEM/VLB 1 .0) cells are incubated with 200 nM [ 3 H]-IVM (FIG. 2A) or [ 3 H]-vinblastine (FIG. 2B) in ⁇ -MEM for 30 minutes at 37° C. in the absence or presence of a 300-fold molar excess of ivermectin (Ivm), vinblastine (Vlb), colchicine (Col), verapamil (Vrp) or cyclosporin A (CsA).
  • the accumulation values represents mean ⁇ SD of three experiments.
  • FIG. 3 shows the saturation binding of ivermectin to resistant cell plasma membranes.
  • Plasma membranes (20 ⁇ g) are incubated with increasing concentrations (0-80 nM) of [ 3 H]-IVM. The nonspecific binding is half of total binding.
  • a Scatchard plot is used to calculate the dissociation constant (K D ) and maximal binding value (B max ) Each value represents mean ⁇ S.E.M. from three experiments.
  • FIGS. 4A and 4B show the competitive inhibition of ivermectin and vinblastine binding to membranes from drug-sensitive and drug-resistant cells.
  • Plasma membranes (20 ⁇ g) from CEM or CEM/VLB 1 .0 cells are incubated with 20 nM [ 3 H]-IVM (FIG. 4A) or [ 3 H]-VLB (FIG. 4B) in the absence or presence of 300-fold molar excess of ivermectin (Ivm), vinblastine (Vlb), colchicine (Col), verapamil (Vrp) or cyclosporin A (CsA).
  • Ivm ivermectin
  • Vlb vinblastine
  • Col colchicine
  • Vrp verapamil
  • CsA cyclosporin A
  • FIGS. 5A and 5B show the competitive inhibition of iodoaryl-azidoprazosin (IAAP) photoaffinity labelling.
  • IAAP iodoaryl-azidoprazosin
  • FIG. 5A drug-sensitive (CEM) and drug-resistant (CEM/VLB 1 .0) cells are photoaffinity labelled with 20 nM [ 125 I]-IAAP.
  • FIG. 5B shows the percent inhibition of IAAP Pgp photolabelling from FIG. 5A as determined from densitometric scanning of Pgp photolabelled band.
  • the signal in lane 2 photolabelled Pgp in CEM/VLB 1 .0 cells in the absence of drugs is taken as control or 100%.
  • FIGS. 6A and 6B show the modulation of vinblastine resistance (FIG. 6A) and doxorubicin resistance (FIG. 6B) by ivermectin, SDZ-PSC 833 (PSC 833), cyclosporin A and verapamil.
  • Drug-sensitive (CEM; 0.5 ⁇ 10 4 ) and drug-resistant (CEM/VLB 0 .1 ; 1 ⁇ 10 4 ) cells are plated and incubated for 24 hours.
  • Vinblastine or doxorubicin is then added (0-5 Mg/mL or 0-10 g/mL, respectively) in the absence and in the presence of IVM, SDZ-PSC 833 (PSC 833), cyclosporin A, or verapamil (0.1, 0.5 or 2 ⁇ M).
  • IVM interleukin-derived doxorubicin
  • PSC 833 SDZ-PSC 833
  • cyclosporin A cyclosporin A
  • verapamil 0.1, 0.5 or 2 ⁇ M.
  • the viability of CEM and CEM/VLB 0 .1 are estimated by measuring the absorbance at 450 nm. Each point is the mean ( ⁇ SD) of three independent experiments.
  • FIG. 7 shows the competitive inhibition of iodoaryl-azidoprazosin photoaffinity labelling.
  • Drug-sensitive (CEM) and drug-resistant (CEM/VLB 1 .0) cells are photoaffinity labelled with 20 nM [ 125 I]-IAAP.
  • Drug-sensitive (Wt) and drug-resistant cells are incubated in the absence (Ctl) or presence of 200-fold (L) or 1000-fold (H) molar excess of ivermectin (Ivm), moxidectin (Mox), cyclosporin A (CsA), vinblastine (Vlb), verapamil (Vrp) and colchicine (Col).
  • FIGS. 8A and 8B show the competitive inhibition of iodoaryl-azidoprazosin photoaffinity labelling by different moxidectin analogues.
  • drug-sensitive (CEM) and drug-resistant (CEM/VLB 1 .0) cells are photoaffinity labelled with 20 nM [ 125 I]-IAAP.
  • FIG. 8B shows the densitometric scanning analysis of the autoradiogram.
  • the multidrug resistant reversing agents comprise macrocyclic lactone compounds.
  • the macrocyclic lactone compounds for use in this invention are either isolated from Streptomyces, such as, for example, the LL-F28249 compounds, the milbemycins, the avermectins and the like or synthetically derived therefrom.
  • Such macrocyclic lactones include, but are not limited to, the LL-F28249 ⁇ - ⁇ compounds, the 23-oxo or 23-imino derivatives thereof, the 22,23-dihydro derivatives of the avermectins and various milbemycin derivatives.
  • Particularly desirable macrocyclic lactone compounds are LL-F28249 ⁇ , 23-(O-methyloxime)-LL-F28249 ⁇ , 23-(semicarbazone)-LL-F28249 ⁇ , 23-(thiosemicarbazone)-LL-F28249 ⁇ , the isomeric mixture of (E) and (Z)-26-formyl-(O-methyloxime)-LL-F28249 ⁇ , ivermectin, abamectin, doramectin, eprinomectin, milbemycin A, milbemycin D and the biological equivalents thereof.
  • the chemotherapeutic agents may include, but are not limited to, the cytostatic hydrophobic chemotherapeutic drugs such as, for example, vinblastine, vincristine, doxorubicin, paclitaxel, colchicine, actinomycin D, gramicidin D and the like. It has been problematic in the use of these chemotherapeutic agents that resistant tumor cells have developed over the past few years. In particular, resistance has been observed in human lymphoma cells, human breast cancer cells, human ovarian cancer cells and human lung cancer cells. The present methods will be beneficial to combatting these and other similar cancerous tissues.
  • the cytostatic hydrophobic chemotherapeutic drugs such as, for example, vinblastine, vincristine, doxorubicin, paclitaxel, colchicine, actinomycin D, gramicidin D and the like. It has been problematic in the use of these chemotherapeutic agents that resistant tumor cells have developed over the past few years. In particular, resistance has been observed in human lymphoma
  • the compounds are administered to mammals orally, parenterally, topically (local activity) or transdermally (systemic activity) depending upon the bioavailability of the selected medicinal by the desired route of administration.
  • Parenteral administration of medicinals encompasses any means other than orally, such as, for example, intravenously, intramuscularly, subcutaneously, intratracheally, intraruminally, etc. It is apparent that the MDR-reversing agents are administered in connection with the administration of the chemotherapeutic agents encountering resistance. However, the administration of the macrocyclic lactones may be made either before or during chemotherapy.
  • the MDR-reversing agent will be given before the chemotherapeutic drug, medical or veterinary personnel can readily determine from blood levels how far in advance the MDR-reversing agent may be given before chemotherapy for efficacy.
  • the selected dosage and the state of the disease influences the timing of administration.
  • the MDR-reversing agent will be administered within 24 hours of the onset of chemotherapy and, preferably, within 4 hours before or concomitantly with administering the chemotherapeutic drug.
  • the MDR-reversing agent may even be administered up to 8 days prior to the start of chemotherapy and still be effective for enhancing the potency of the chemotherapeutic agent.
  • the suitable amount of the macrocyclic lactone compounds which is effective to increase the toxicity of the chemotherapeutic agent against resistant tumors and other cells will typically vary within a wide range of amounts at a variety of concentrations.
  • the nature or state of the disease and the selection of the chemotherapeutic agent will clearly affect the particular dose of the MDR-reversing agent.
  • the macrolides may be given, for instance, at the dosage of about 0.001 mg to about 10 mg per kg of body weight and preferably, about 1 mg to about 5 mg per kg of body weight. Other circumstances may warrant dosages either above or below this level. It is contemplated that selection of appropriate dosages of the chemotherapeutic agent and the multidrug resistant reversing agent to achieve the effective tumor suppressing amount can be easily titrated by routine testing known to those having ordinary skill in the medical and veterinary arts.
  • the compounds of the present invention may be administered orally in a unit dosage form such as a capsule, bolus or tablet.
  • the capsules and boluses comprise the active ingredient admixed with a conventional carrier vehicle such as starch, talc, magnesium stearate or dicalcium phosphate.
  • a conventional carrier vehicle such as starch, talc, magnesium stearate or dicalcium phosphate.
  • the dry, solid unit dosage form are prepared by intimately and uniformly mixing the active ingredient with suitable finely divided diluents, fillers, disintegrating agents and/or binders such as starch, lactose, talc, magnesium stearate, vegetable gums and the like.
  • Such unit dosage formulations may be widely varied with respect to their total weight and content of the active agent depending upon factors such as the type and the weight of the mammal to be treated, the severity of the disease state and the type of tumor involved.
  • the active compound can be administered via an animal feedstuff by intimately dispersing the active ingredient in the feed or using it as a top dressing or in the form of pellets which may then be added to the finished feed or optionally fed separately.
  • Suitable compositions include feed premixes or supplements in which the active compound is present in relatively large amounts, wherein said feed premixes or supplements are suitable for direct feeding to the animal or for addition to the feed either directly or after an intermediate dilution or blending step.
  • Typical carriers or diluents suitable for such compositions include distillers' dried grains, corn meal, citrus meal, fermentation residues, ground oyster shells, wheat products, molasses, corn cob meal, edible bean mill feed, soya grits, crushed limestone, etc.
  • the compounds are intimately dispersed throughout the carrier by methods such as grinding, stirring, milling or tumbling.
  • Compositions containing about 0.005% to about 2.0%, by weight, of the active compound are particularly suitable as feed premixes.
  • Feed supplements fed directly to the animal contain about 0.0002% to 0.3%, by weight, of the active compounds. Such supplements are added to animal feed in an amount to give the finished feed the concentration of active compound desired for treating the resistant tumor or other cancerous disease.
  • the desired concentration of the compound will vary depending upon a variety of factors such as the particular compound employed or the severity of the disease state, the macrocyclic compounds of this invention are usually fed at concentrations of about 0.00001% to about 0.02% in the feed.
  • the active ingredients of the invention may be administered to the affected mammals parenterally.
  • the macrocyclic compounds may be dissolved, dispersed or suspended in a sterile, isotonic, nontoxic liquid carrier vehicle.
  • the compound is admixed with the nontoxic pharmaceutically acceptable vehicle, preferably a vegetable oil such as peanut oil, cotton seed oil or the like.
  • the nontoxic pharmaceutically acceptable vehicle preferably a vegetable oil such as peanut oil, cotton seed oil or the like.
  • Other parenteral vehicles such as propylene glycol, glycerol, etc. may also be used.
  • a parenteral formulation comprising the macrolides and the chemotherapeutic agents may be lyophilized with optional excipients and reconstituted prior to administration using a suitable nontoxic pharmaceutically acceptable vehicle such as sterile saline, glucose in water, water, etc.
  • the active macrolides are typically dissolved or suspended in the formulation in sufficient amount to provide from about 0.005% to about 5.0%, by weight, of the active compound in said formulation.
  • the macrolides may also be administered to the affected mammals by the topical or transdermal route to achieve either local or systemic effect.
  • the compounds may be applied as a liquid drench.
  • the drench is normally a solution, suspension or dispersion of the active compound, usually in water, together with a suspending agent such as bentonite and a wetting agent or similar excipient.
  • the drenches also contain an antifoaming agent.
  • Drench formulations typically contain about 0.001% to about 0.5%, by weight, and preferably, about 0.01% to about 0.1%, by weight, of the active macrocyclic compound.
  • the macrocyclic compounds and certain chemotherapeutic agents may be administered by applying as a gel, lotion, solution, cream or ointment to human skin or pouring on animal skin or hide via a solution.
  • the topical or transdermal formulations comprise the active ingredient in combination with conventional inactive excipients and carriers.
  • the cream for example, may use liquid petrolatum, white petrolatum, propylene glycol, stearyl alcohol, cetyl alcohol, sodium lauryl sulfate, sodium phosphate buffer, polysorbates, parabens, emulsifying wax, polyoxyethylene-polyoxypropylene block copolymers, purified water and the like.
  • Ointments may employ petrolatum, mineral oil, mineral wax, glycerin and the like.
  • Topical solutions may provide the active ingredient compounded with propylene glycol, parabens, hydroxypropyl cellulose, preservatives.
  • Pour-on formulations may constitute the active ingredient dissolved in a suitable inert solvent, such as dimethylsulfoxide, propylene glycol and the like.
  • a particularly useful pour-on formulation comprises the active ingredient dissolved or dispersed in an aromatic solvent, PPG-2 myristyl ether propionate, polybutene, an antimicrobial agent, an antioxidant and a nontoxic pharmaceutically acceptable mineral or vegetable oil.
  • the macrocyclic lactone compounds such as moxidectin, a number of moxidectin analogues and ivermectin are potent P-glycoprotein binding drugs and that they can reverse multidrug resistance (MDR) in tumor and other cells.
  • MDR multidrug resistance
  • the results illustrate that IVM, for example, is a substrate for the Pgp drug efflux pump.
  • IVM interacts with Pgp and surprisingly is a potent MDR-reversing agent.
  • the macrocyclic lactone compounds can play an important role in cancer therapy and other diseases in which MDR can be problematic.
  • MDR-reversing agents While some of the moxidectin analogues are shown to be marginally active as endectocides, they are surprisingly very potent MDR-reversing agents. This makes them useful as MDR-reversing agents either in cancer therapy or as reversing agents of endectocide resistance in nematodes and arthropods.
  • IVM is a substrate for the Pgp drug efflux pump in human mdr cells.
  • the results illustrate that [ 3 H]-IVM accumulates to a lesser extent in drug-resistant than in drug-sensitive cells.
  • the efflux studies show that [ 3 H]-IVM is effluxed rapidly from resistant cells and this transport is energy-dependent.
  • IVM infrared voltascopy
  • IVM can possess a slower dissociation constant than vinblastine (K D is 10.6 nM versus 400-500 nM for IVM and vinblastine, respectively) (Naito et al., ATP/Mg2+-dependent binding of vincristine to the plasma membrane of multidrug-resistant K562 cells, J. Biol. Chem.
  • nonionic detergents which also reverse the mdr-phenotype at nontoxic concentrations, it has been previously demonstrated that hydrophobic interactions are likely to mediate Pgp drug binding, while the cationic charge associated with some lipophilic MDR-reversing agents may be important in drug transport (Zordan-Nudo et al., Effects of nonionic detergents on P-glycoprotein drug binding and reversal of multidrug resistance, Cancer Res. 53: 5994-6000, 1993).
  • the octanol/water fractionation coefficient of IVM is 3- and 9-fold higher than that of cyclosporin A and verapamil, respectively.
  • K ow 58,300
  • cyclosporin and verapamil a significantly higher octanol/water fractionation coefficient
  • the observed differences in the reversing potential seen with the MDR-reversing agents with respect to their hydrophobicity are consistent with earlier findings (Zordan-Nudo et al., Effects of nonionic detergents on P-glycoprotein drug binding and reversal of multidrug resistance, Cancer Res. 53: 5994-6000, 1993; Nogae et al., Analysis of structural features of dihydropyridine analogs needed to reverse multidrug resistance and to inhibit photoaffinity labelling of P-glycoprotein, Biochem. Pharmacol.
  • vinblastine or cyclosporin A which interact with Pgp are shown to potentiate IVM accumulation in drug-resistant cells and to inhibit the binding of [ 3 H]-IVM to membranes from drug-resistant, but not from drug-sensitive cells.
  • the failure of verapamil to inhibit [ 3 H]-IVM binding to plasma membranes is not clear. It may be speculated that IVM interacts with different sequences in Pgp than that of verapamil.
  • Competitive inhibition of [ 3 H]-vinblastine and [ 3 H]-IVM binding to membranes from resistant cells shows that IVM completely inhibits [ 3 H]-VLB binding, while vinblastine only partially inhibits [ 3 H]-IVM binding.
  • Cyclosporin A is the only drug that totally inhibits IVM binding to Pgp. This suggests that these two drugs interact with similar binding sites.
  • IVM is more efficient than SDZ-PSC 833 at inhibiting Pgp photoaffinity labelling with IAAP.
  • the IC 50 for SDZ-PSC 833 is 1.2-fold lower than that of IVM for both VLB (vinblastine) and DOXO (doxorubicin); yet, it is also inherently more toxic to drug-sensitive and drug-resistant cells. Thus, it is likely that some of the MDR-reversal is due to SDZ-PSC 833 toxicity alone.
  • IVM is well-tolerated at plasma concentrations exceeding 680 ng/mL.
  • IVM possesses a long half-life that varies between 1 and 8 days according to species and the biological transformation rate is relatively slow (less than 50% after 14 days) (Chiu et al., Absorption, tissue distribution, and excression of tritium-labeled ivermectin in cattle, sheep and rat, J. Agric. Food. Chem. 38: 2072-2078, 1990).
  • IVM has an unexpected advantage over SDZ-PSC 833 in reversing the mdr phenotype of tumors in clinical application.
  • the moxidectin series of compounds and ivermectin exemplify high P-glycoprotein binding affinity indicating that the macrocyclic lactone compounds can act as multidrug resistance reversing agents.
  • a number of the moxidectin analogues and ivermectin are very potent multidrug reversing agents and can have application in cancer treatment and other circumstances in which multidrug resistance is problematic.
  • These compounds can be used therapeutically in any mammal including animals or humans. While it is highly desirable to treat cancer affecting pets such as dogs, cats and horses, the compounds would find application in other farm or zoo animals as well.
  • their safety and multidrug resistance potency present real advantages for chemotherapy in humans compared with other multidrug resistance reversing agents which have significant side effects.
  • This invention further describes a new derivative of the LL-F28249 family of macrolides which has potent multidrug resistance reversing properties.
  • the novel isomeric mixture of (E) and (Z)-26-formyl-(o-methyloxime)-LL-F28249 ⁇ has the following structure: ##STR1##
  • the isomeric mixture of (E) and (Z)-26-formyl-(O-methyloxime)-LL-F28249 ⁇ may be prepared from LL-F28249 ⁇ .
  • the reaction sequence is illustrated in greater detail as follows: As the starting material, LL-F28249 ⁇ (30.3 g, 4.9 mmol) is dissolved in acetone (60 mL) and water (15 mL). The solution is immersed in an ice bath.
  • N-Bromoacetamide (0.8558 g, 6.2 mmol) in acetone (60 mL) is added dropwise while the solution is under nitrogen, stirring. After the addition is complete, the solution is stirred an additional 45 minutes. Thereafter, the solution is diluted with Et 2 O (350 mL), washed with brine (50 mL), dried over magnesium sulfate and filtered to remove the solvent. The residue is flash chromatographed (SiO 2 using 1.5% isopropanol and CH 2 Cl 2 as eluent before quenching).
  • the allylic bromide (0.234 g, 0.34 mmol) is dissolved in DMSO (4 mL) and AgBF 4 (73.5 mg, 1.1 eq, 0.38 mmol). The solution is stirred at room temperature under nitrogen for 7 hours. Et 3 N (100 ⁇ L) is added dropwise. After stirring an additional 15 minutes, the solution is diluted with 30 mL of water plus 20 mL of brine, and extracted twice with Et 2 O (30 mL each). Combined ethereal layers are then washed with water (10 mL), then brine (5 mL), dried over magnesium sulfate, filtered and the solvent is removed.
  • the aldehyde LL-F28249 ⁇ product (41.0 mg, 65 ⁇ mol) is added to methoxylamine hydrochloride (40 mg, 470 ⁇ mol, 7 eq) and pyridine (0.1 mL) in ethanol (1 mL) and stirred under nitrogen at room temperature. After 17 hours reaction time, the mixture is diluted with toluene and then diluted with Et 2 O (6 mL), washed with water (1 mL), then brine, dried over magnesium sulfate, filtered and the solvent is removed.
  • IVM and [ 3 H]-IVM are supplied by American Cyanamid Company (Princeton, N.J., USA).
  • Cyclosporin A and its non-immunosuppressive analogue SDZ-PSC 833 are supplied by Sandoz Inc. (East Hanover, N.J.).
  • Vinblastine is obtained from Aldrich Chemical Co. (Milwaukee, Wis.)
  • verapamil and colchicine are from Sigma Chemical Co. (St. Louis, Mo.)
  • [ 125 I]-iodoaryl-azidoprazosin (2200 Ci/mmol) is purchased from DuPont New England Nuclear (Boston, Mass.).
  • CEM Drug-sensitive human lymphoma cells
  • the CEM/VLB 1 .0 line is established from the CEM/VLB 0 .1 line and is obtained from the B.C. Cancer Research Centre (Vancouver, B.C.). All other chemicals used are of the highest grade available.
  • CEM and CEM/VLB 1 .0 cells are grown in ⁇ -minimal Eagle's Medium (MEM) by conventional methods (e.g., Beck, Vinca alkaloid-resistant phenotype in cultured human leukemic lymphoblasts, Cancer Treat. Rep. 67: 875-882, 1983).
  • MEM ⁇ -minimal Eagle's Medium
  • the CEM/VLB 1 .0 cells are resistant to 1 ⁇ g/mL vinblastine and express high levels of Pgp compared to the sensitive cells (Zordan-Nudo et al., Effects of nonionic detergents on P-glycoprotein drug binding and reversal of multidrug resistance, Cancer Res. 53: 5994-6000, 1993).
  • Plasma membranes are prepared using a calcium precipitation procedure essentially as described by Lin et al., Biochemistry 26: 731-736, 1987. Briefly, CEM and CEM/VLB 1 .0 cells are washed three times in ice-cold phosphate buffered saline (PBS) and resuspended in a hypotonic lysis buffer (10 mM KCl, 1.5 mM MgCl 2 , and 10 mM Tris-HCl, pH 7.4) containing protease inhibitors (2 mM phenylmethylsulfonyl fluoride, 30 ⁇ M leupeptin and pepstatin).
  • PBS ice-cold phosphate buffered saline
  • a hypotonic lysis buffer (10 mM KCl, 1.5 mM MgCl 2 , and 10 mM Tris-HCl, pH 7.4
  • protease inhibitors 2 mM phenylmethylsulfonyl fluor
  • Cells are homogenized using a Dounce glass homogenizer and the cell lysate is centrifuged at low speed (3000 g) to remove unbroken cells and nuclei.
  • the resultant supernatant is made up to 10 mM CaCl 2 final concentration and mixed on ice.
  • the calcium-induced membrane aggregates are precipitated by high speed centrifugation at 100,000 g for 1 hour at 4° C. using a Beckman SW50 rotor.
  • the enriched plasma membrane pellet is washed with 10 mM Tris-HCl, pH 7.4, and 250 mM sucrose and stored at -80° C. until needed.
  • the protein concentration is measured by the method of Bradford, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding, Anal. Biochem. 72: 248-254, 1976.
  • Cells, cultured without drug for at least 1 week, are harvested in the exponential growth phase, and 100 ⁇ L aliquots are plated into 96-well plates at 0.5 ⁇ 10 4 for CEM and 1 ⁇ 10 4 for CEM/VLB per well.
  • the cells are incubated for 24 hours at 37° C. before the addition of vinblastine plus/minus MDR-reversing agents.
  • the cells are then cultured for 4 days and the MTT dye (3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl tetrazolium bromide) is added to a final concentration of 0.5 mg/mL.
  • the plates are incubated for 4 hours at 37° C.
  • TRITON X-100® a mixture of polyoxyethylene ethers commercially available from Sigma Chemical Company, St. Louis, Mo.
  • the 96-well plates are heated in the microwave oven for 1 minute at the minimal power setting, and 10 ⁇ L of ethanol is added to disperse the bubbles formed during pipetting. Plates are read at 570 nM using an ELISA micro titer plate reader.
  • CEM and CEM/VLB 1 .0 cells (1 ⁇ 10 6 ) are washed 3 times in A-MEM and incubated in the dark for 30 minutes at 25° C. in the presence of 20 nM [ 125 I]-aryl-azidoprazosin (IAAP) with or without 1, 10, and 100-fold molar excess of IVM, SDZ-PSC 833, cyclosporin A, vinblastine or verapamil.
  • the cells are set on ice for 10 minutes and irradiated with a 254 nm UV source (Stratagene UV crosslinker, Stratagene, La Jolla, Calif.).
  • Plasma membranes from CEM and CEM/VLB 1 .0 cells (20 ⁇ g) are preincubated in 10 mM Tris pH 7.4 containing 250 mM sucrose (TS) for 30 minutes at 37° C. in the presence of a 300-fold molar excess of unlabelled drugs (IVM, cyclosporin A, vinblastine, verapamil or colchicine). The cells are then incubated for 30 minutes at 37° C. in the presence of 20 nM [ 3 H]-IVM or vinblastine. The incubation is stopped with the addition of 1 mL of ice-cold TS. The membranes are washed twice with the same volume of TS and the membrane pellet is resuspended in 1 M NaOH and neutralized with the same volume of 1 M HCl 4 hours later. Drug binding is evaluated by liquid scintillation counting.
  • CEM and CEM/VLB 1 .0 cells (1 ⁇ 10 6 ) are washed 3 times in PBS containing 1 mg/mL glucose and preincubated for 30 minutes at 37° C. in the presence of 300-fold molar excess of unlabelled drugs (IVM, cyclosporin A, vinblastine, verapamil or colchicine). Cells are then incubated for 30 minutes at 37° C. in the presence of 0.2 ⁇ M [ 3 H]-IVM or [ 3 1H]-vinblastine in a final volume of 100 ⁇ L. The incubation is stopped with the addition of 1 mL of ice-cold PBS containing 60 ⁇ M unlabelled IVM or vinblastine. Cells are then washed twice with the same stop solution and lysed in 100 ⁇ L of 1 M NaOH followed by neutralization with the same volume of 1 M HCl, 4 hours later.
  • IVM unlabelled drugs
  • cells are preincubated for 30 minutes at 37° C. in the presence of 2 ⁇ M [ 3 H]-IVM or [ 3 H]-vinblastine and 10 mM sodium azide to inhibit drug efflux.
  • Cells are washed and resuspended in PBS solution containing 1 mg/mL of glucose at 37° C. Samples are removed following 0-30 minute incubations. Cells are washed in 10 volumes of ice-cold PBS containing 2 ⁇ M of unlabelled drug. The final cell pellet is resuspended in 1 M NaOH followed by neutralization with the same volume of 1 M HCl, 4 hours later.
  • the accumulation of labelled drugs is measured by liquid scintillation counting.
  • Drugs are solubilized in octanol and mixed with an equal volume of PBS and strongly vortexed. After 30 minutes of agitation, the mixture is centrifuged at 1000 g for 5 minutes.
  • the upper (octanol) phase is separated from the lower (PBS) phase using a Pasteur pipette.
  • the amount of drug in both phases is determined by measuring the UV absorbance.
  • the drugs are separated by high performance liquid chromatography (HPLC) to increase the sensitivity of the detection.
  • FIGS. 1A and 1B show the accumulation and efflux of [ 3 H]-IVM or [ 3 H]-VLB in drug-sensitive (CEM) and drug-resistant (CEM/VLB 1 .0) cells.
  • CEM drug-sensitive
  • CEM/VLB 1 .0 drug-resistant cells
  • [ 3 H]-IVM levels are measured in CEM and CEM/VLB 1 .0 cells in the absence and in the presence of 300-fold molar excess of IVM, VLB, colchicine, verapamil, or cyclosporin A (FIG. 2A).
  • FIG. 1A reveals higher levels of [ 3 H]-IVM accumulation in sensitive cells compared to resistant cells.
  • the presence of unlabelled IVM, cyclosporin A or verapamil increases the accumulation of [ 3 H]-IVM to the same extent as that found in CEM cells, while vinblastine and colchicine are without effect (FIG. 2A).
  • the ⁇ 1 -adrenergic receptor ligand iodoaryl-azidoprazosin (IAAP)
  • IAAP iodoaryl-azidoprazosin
  • FIG. 5A show a 170 kDa photolabelled protein in membranes from resistant but not from drug-sensitive cells (lanes 2 and 1, respectively).
  • the presence of 100-fold excess of IVM, and SDZ-PSC 833 completely inhibits the photolabelling of Pgp with IAAP (lanes 3 and 6).
  • Similar molar excess of cyclosporin A or verapamil are less effective (lanes 9 and 12).
  • IVM at 10-fold molar excess is more effective than SDZ-PSC 833 in inhibiting the photolabelling of Pgp with IAAP (lanes 4 and 7).
  • IVM doxorubicin
  • CEM or CEM/VLB 0 .1 cells are incubated with increasing concentrations of vinblastine or doxorubicin in the absence or in the presence of IVM, SDZ-PSC 833, cyclosporin A or verapamil (0, 0.1, 0.5 or 2 ⁇ M).
  • the potentiation of drug toxicity by IVM and other MDR-reversing agents is determined by the MTT cytotoxicity assay (FIGS. 6A and 6B).
  • the IC 50 values for vinblastine or doxorubicin for CEM and CEM/VLB 0 .1 are 3.5 ng/mL and 500 ng/mL or 25 ng/mL and 1100 ng/mL, respectively.
  • the presence of IVM, cyclosporin A, and verapamil alone has no significant effect on the viability of CEM or CEM/VLB 0 .1 cells (FIGS. 6A and 6B).
  • SDZ-PSC 833 a potent MDR-reversing agent (Watanabe et al., Comparative study on reversal efficacy of SDZ-PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo, Acta Oncol. 34: 235-241, 1995), at 2 ⁇ M is toxic to both CEM and CEM/VLB 0 .1 cells (FIGS. 6A and 6B).
  • Table 1 shows the IC 50 of CEM/VLB 0 .1 cells to vinblastine or doxorubicin in the presence of increasing concentrations of IVM, SDZ-PSC 833, cyclosporin A and verapamil.
  • IVM at 2 ⁇ M is approximately 9-fold and approximately 4-fold better than verapamil and cyclosporin A in potentiating the toxicity of vinblastine or doxorubicin (FIG. 6A, FIG. 6B and Table 1).
  • SDZ-PSC 833 is approximately 1.2-fold better than IVM in potentiating the toxicity of vinblastine or doxorubicin.
  • SDZ-PSC 833 alone is much more toxic to CEM and CEM/VLB 0 .1 cells (FIGS. 6A and 6B).
  • the hydrophobicity of IVM is evaluated using octanol/water fractionation coefficient and compared to other Pgp-associated drugs or MDR-reversing agents.
  • the results in Table 2 show the octanol/water fractionation coefficients for colchicine, vinblastine, verapamil, cyclosporin A and IVM, to be 14, 30, 145, 518 and 1358, respectively.
  • the latter coefficients are compared with respect to the ability of drugs to inhibit binding, transport, or reverse the MDR of CEM/VLB 1 .0 cells (Table 2), a strong correlation between hydrophobicity and these parameters can be observed. However, some exceptions are observed.
  • verapamil which is more hydrophobic than vinblastine, is a better inhibitor of drug transport, although photolabelling and binding are preferentially inhibited by vinblastine.
  • avermectin as a multidrug reversing agent
  • macrocyclic lactone compounds such as moxidectin and various moxidectin analogs, as multidrug resistance reversing agents are illustrated herein.
  • moxidectin derivatives are also assessed for their ability to displace IAAP photoaffinity labelling.
  • the ability to block azidoprazosin binding of P-glycoprotein evidences their likely activity as multidrug resistance reversing agents.
  • Photolabelling experiments are performed with 5 different analogues of moxidectin (FIGS. 8A and 8B).
  • the moxidectin analogues appear to possess a strong affinity for P-glycoprotein and to be good MDR-reversing agents. All the moxidectin analogues tested are highly hydrophobic, and are found to interact with P-glycoprotein.
  • Both charged analogues 23-(thiosemicarbazone)-LL-F28249 ⁇ and 23-(semicarbazone)-LL-F28249 ⁇ are found to be better inhibitors of IAAP photolabelling than moxidectin, showing a 15 to 20% higher displacement compared to moxidectin at the inhibitor level of a 1000-fold molar excess.
  • An excellent photolabelling inhibitor is the isomeric mixture of (E) and (Z)-26-formyl-(O-methyloxime)-LL-F28249 ⁇ , which shows a 30% to 40% increase in displacement, compared with moxidectin, at an inhibitor concentration of 1000-fold molar excess. The results indicate that this molecule possesses powerful multidrug resistance reversing properties.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
US09/067,677 1997-04-30 1998-04-28 Methods for using macrocyclic lactone compounds as multidrug resistance reversing agents in tumor and other cells Expired - Fee Related US6114376A (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
US09/067,677 US6114376A (en) 1997-04-30 1998-04-28 Methods for using macrocyclic lactone compounds as multidrug resistance reversing agents in tumor and other cells
DK98917538T DK0979089T3 (da) 1997-04-30 1998-04-29 Fremgangsmåder til anvendelse af makrocykliske lacton-forbindelser som multilægemiddel-resistens-reverterende midler i tumor og andre celler
EP98917538A EP0979089B1 (fr) 1997-04-30 1998-04-29 Procedes d'utilisation de composes de lactone macrocycliques en qualite d'agents d'inversion de la resistance aux medicaments polyvalents dans des cellules cancereuses et autres
DE69832375T DE69832375T2 (de) 1997-04-30 1998-04-29 Verwendungsmethoden makrocyklischer lactonverbindungen als mittel zur umkehr der mehrfach-arzneimittelresistenz in tumor-und anderen zellen
CA002289086A CA2289086C (fr) 1997-04-30 1998-04-29 Procedes d'utilisation de composes de lactone macrocycliques en qualite d'agents d'inversion de la resistance aux medicaments polyvalents dans des cellules cancereuses et autres
ES98917538T ES2252832T3 (es) 1997-04-30 1998-04-29 Procedimientos de utilizacion de compuestos de lactona macrociclicos en calidad de agentes de inversion de la resistencia a los medicamentos polivalentes en celulas cancerosas y otras.
PCT/IB1998/000750 WO1998048813A1 (fr) 1997-04-30 1998-04-29 Procedes d'utilisation de composes de lactone macrocycliques en qualite d'agents d'inversion de la resistance aux medicaments polyvalents dans des cellules cancereuses et autres
AU70736/98A AU744406B2 (en) 1997-04-30 1998-04-29 Methods for using macrocyclic lactone compounds as multidrug resistance reversing agents in tumor and other cells
NZ500429A NZ500429A (en) 1997-04-30 1998-04-29 Methods for using macrocyclic lactone compounds such as milbemycin and avermectin in combination with chemotherapeutic agents in tumor and other cells
AT98917538T ATE309805T1 (de) 1997-04-30 1998-04-29 Verwendungsmethoden von makrozyklischen laktonen als mittel zur umkehrung der mehrfach- medikamentresistenz in krebs- und anderen zellen

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4516197P 1997-04-30 1997-04-30
US09/067,677 US6114376A (en) 1997-04-30 1998-04-28 Methods for using macrocyclic lactone compounds as multidrug resistance reversing agents in tumor and other cells

Publications (1)

Publication Number Publication Date
US6114376A true US6114376A (en) 2000-09-05

Family

ID=26722446

Family Applications (1)

Application Number Title Priority Date Filing Date
US09/067,677 Expired - Fee Related US6114376A (en) 1997-04-30 1998-04-28 Methods for using macrocyclic lactone compounds as multidrug resistance reversing agents in tumor and other cells

Country Status (10)

Country Link
US (1) US6114376A (fr)
EP (1) EP0979089B1 (fr)
AT (1) ATE309805T1 (fr)
AU (1) AU744406B2 (fr)
CA (1) CA2289086C (fr)
DE (1) DE69832375T2 (fr)
DK (1) DK0979089T3 (fr)
ES (1) ES2252832T3 (fr)
NZ (1) NZ500429A (fr)
WO (1) WO1998048813A1 (fr)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312336B1 (en) * 1998-02-13 2001-11-06 Nds Limited Electronic game guide system
US20020132689A1 (en) * 1996-12-19 2002-09-19 Young James D. Roller chain sprocket with added chordal pitch reduction
US20020144265A1 (en) * 2001-03-29 2002-10-03 Connelly Jay H. System and method for merging streaming and stored content information in an electronic program guide
US20020144269A1 (en) * 2001-03-30 2002-10-03 Connelly Jay H. Apparatus and method for a dynamic electronic program guide enabling billing broadcast services per EPG line item
US20020167947A1 (en) * 2001-05-11 2002-11-14 Hallford Jason C. Method and apparatus for combining broadcast schedules and content on a digital broadcast-enabled client platform
US20020193066A1 (en) * 2001-06-15 2002-12-19 Connelly Jay H. Methods and apparatus for providing rating feedback for content in a broadcast system
US20020194598A1 (en) * 2001-06-15 2002-12-19 Connelly Jay H. Method and apparatus for continuously and opportunistically driving an optimal broadcast schedule based on most recent client demand feedback from a distributed set of broadcast clients
US20020194607A1 (en) * 2001-06-15 2002-12-19 Connelly Jay H. Method and apparatus for periodically delivering an optimal batch broadcast schedule based on distributed client feedback
US20020194585A1 (en) * 2001-06-15 2002-12-19 Connelly Jay H. Methods and apparatus for providing ranking feedback for content in a broadcast system
US20030005301A1 (en) * 2001-06-28 2003-01-02 Jutzi Curtis E. Apparatus and method for enabling secure content decryption within a set-top box
US20030016673A1 (en) * 2001-06-29 2003-01-23 Ramesh Pendakur Correcting for data losses with feedback and response
US20030046708A1 (en) * 2001-08-28 2003-03-06 Jutzi Curtis E. Error correction for regional and dynamic factors in communications
US20030046683A1 (en) * 2001-08-28 2003-03-06 Jutzi Curtis E. Server-side preference prediction based on customer billing information to generate a broadcast schedule
US20030109448A1 (en) * 2001-11-07 2003-06-12 Crowley Kathleen S. Methods of promoting uptake and nuclear accumulation of polyamides in eukaryotic cells
US20030135553A1 (en) * 2002-01-11 2003-07-17 Ramesh Pendakur Content-based caching and routing of content using subscription information from downstream nodes
US20030135605A1 (en) * 2002-01-11 2003-07-17 Ramesh Pendakur User rating feedback loop to modify virtual channel content and/or schedules
US20030135857A1 (en) * 2002-01-11 2003-07-17 Ramesh Pendakur Content discovery in a digital broadcast data service
US7167895B1 (en) 2000-03-22 2007-01-23 Intel Corporation Signaling method and apparatus to provide content on demand in a broadcast system
US7231653B2 (en) 2001-09-24 2007-06-12 Intel Corporation Method for delivering transport stream data
US7275254B1 (en) 2000-11-21 2007-09-25 Intel Corporation Method and apparatus for determining and displaying the service level of a digital television broadcast signal
US7962573B2 (en) 2000-03-21 2011-06-14 Intel Corporation Method and apparatus to determine broadcast content and scheduling in a broadcast system
WO2014152864A1 (fr) * 2013-03-14 2014-09-25 Panacea Pharmaceuticals Traitement d'un déficit cognitif induit par une chimiothérapie
US20140371164A1 (en) * 2011-12-20 2014-12-18 Ectin Research Ab Synergistic Combination Comprising Avermectins and a NSAID for Tumor Inhibition
US8943540B2 (en) 2001-09-28 2015-01-27 Intel Corporation Method and apparatus to provide a personalized channel
CN112898224A (zh) * 2019-12-04 2021-06-04 中国科学院上海药物研究所 一种烯丙基醇支撑的大环内酯化合物及其用途

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495591B1 (en) * 1997-10-02 2002-12-17 Essential Therapeutics, Inc. Fungal efflux pump inhibitors
DE102007013765A1 (de) * 2007-03-22 2008-09-25 Studiengesellschaft Kohle Mbh Lejimalid Analoga und Verwendung davon
WO2011054103A1 (fr) * 2009-11-09 2011-05-12 University Health Network Utilisation de combinaisons synergiques de composés d'avermectine et de composés antinéoplasiques en vue du traitement de cancers hématologiques
WO2012150543A1 (fr) 2011-05-02 2012-11-08 Universite De Geneve Lactones macrocycliques et leur utilisation
CN115227691B (zh) * 2022-06-15 2023-05-05 福建卫生职业技术学院 源于细曲霉的内酯类化合物在抗人乳腺癌药物中的应用

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3950360A (en) * 1972-06-08 1976-04-13 Sankyo Company Limited Antibiotic substances
US4199569A (en) * 1977-10-03 1980-04-22 Merck & Co., Inc. Selective hydrogenation products of C-076 compounds and derivatives thereof
US4310519A (en) * 1976-04-19 1982-01-12 Merck & Co., Inc. Novel substances and process for their production
US4916154A (en) * 1986-09-12 1990-04-10 American Cyanamid Company 23-Imino derivatives of LL-F28249 compounds
US5106994A (en) * 1984-06-05 1992-04-21 American Cyanamid Company Agents and method of production thereof
JPH04235126A (ja) * 1991-01-09 1992-08-24 Nippon Kayaku Co Ltd 耐性癌細胞に対する感受性増強剤
US5169956A (en) * 1984-06-05 1992-12-08 American Cyanamid Company Macrolide antibiotic compounds
WO1994022846A1 (fr) * 1993-03-30 1994-10-13 Pfizer Inc. Composes stimulant l'activite antitumorale d'autres agents cytotoxiques
WO1996001127A1 (fr) * 1994-07-05 1996-01-18 Arch Development Corporation Combinaisons medicamenteuse contenant des camptothecines et medicaments a effets secondaires reduits
US5578637A (en) * 1995-05-03 1996-11-26 University Of Washington Methods of inhibition or killing cancer cells using an endoperoxide

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3950360A (en) * 1972-06-08 1976-04-13 Sankyo Company Limited Antibiotic substances
US4310519A (en) * 1976-04-19 1982-01-12 Merck & Co., Inc. Novel substances and process for their production
US4199569A (en) * 1977-10-03 1980-04-22 Merck & Co., Inc. Selective hydrogenation products of C-076 compounds and derivatives thereof
US5106994A (en) * 1984-06-05 1992-04-21 American Cyanamid Company Agents and method of production thereof
US5169956A (en) * 1984-06-05 1992-12-08 American Cyanamid Company Macrolide antibiotic compounds
US4916154A (en) * 1986-09-12 1990-04-10 American Cyanamid Company 23-Imino derivatives of LL-F28249 compounds
JPH04235126A (ja) * 1991-01-09 1992-08-24 Nippon Kayaku Co Ltd 耐性癌細胞に対する感受性増強剤
WO1994022846A1 (fr) * 1993-03-30 1994-10-13 Pfizer Inc. Composes stimulant l'activite antitumorale d'autres agents cytotoxiques
WO1996001127A1 (fr) * 1994-07-05 1996-01-18 Arch Development Corporation Combinaisons medicamenteuse contenant des camptothecines et medicaments a effets secondaires reduits
US5578637A (en) * 1995-05-03 1996-11-26 University Of Washington Methods of inhibition or killing cancer cells using an endoperoxide

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
Didier et al., Decreased biotolerability for ivermectin & cyclosporin A in mice exposed to potent P glycoprotein inhibitors, Int. J. Cancer 63:263 267 (1995). *
Didier et al., Decreased biotolerability for ivermectin & cyclosporin A in mice exposed to potent P-glycoprotein inhibitors, Int. J. Cancer 63:263-267 (1995).
Didier et al., Decreased uptake of cyclosporin A by P glycoprotein (Pgp) expressing CEM leukemic cells & restoration of normal retention by Pgp blockers, Anti Cancer Drugs 6:669 680 (1995). *
Didier et al., Decreased uptake of cyclosporin A by P-glycoprotein (Pgp) expressing CEM leukemic cells & restoration of normal retention by Pgp blockers, Anti-Cancer Drugs 6:669-680 (1995).
Didier et al., The abamectin derivative ivermectin is a potent P glycoprotein inhibitor, Anti Cancer Drugs 7:745 751 (1996). *
Didier et al., The abamectin derivative ivermectin is a potent P-glycoprotein inhibitor, Anti-Cancer Drugs 7:745-751 (1996).
Greenwald et al., Mechanistic Studies of Passive and Active Transport Processes in MDCK Cells: Transport of Selected Anthelmintics, oral presentation at 41st Annual Meeting, Jul. 20 23, 1996 (KY) AAVP Proceedings abstr. 12. *
Greenwald et al., Mechanistic Studies of Passive and Active Transport Processes in MDCK Cells: Transport of Selected Anthelmintics, oral presentation at 41st Annual Meeting, Jul. 20-23, 1996 (KY) AAVP Proceedings abstr. 12.
Pouliot et al., Reversal of P Glycoprotein Associated Multidrug Resistance by Ivermectin, Biochem. Pharm. 53(1):17 25 (Jan. 10, 1997). *
Pouliot et al., Reversal of P-Glycoprotein-Associated Multidrug Resistance by Ivermectin, Biochem. Pharm. 53(1):17-25 (Jan. 10, 1997).
Schinkel et al., Disruption of the Mouse mdr1a P Glycoprotein Gene Leads to a Deficiency in the Blood Brain Barrier and to Increased Sensitivity to Drugs, Cell 77:491 502 (May 20, 1994). *
Schinkel et al., Disruption of the Mouse mdr1a P-Glycoprotein Gene Leads to a Deficiency in the Blood-Brain Barrier and to Increased Sensitivity to Drugs, Cell 77:491-502 (May 20, 1994).

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020132689A1 (en) * 1996-12-19 2002-09-19 Young James D. Roller chain sprocket with added chordal pitch reduction
US6312336B1 (en) * 1998-02-13 2001-11-06 Nds Limited Electronic game guide system
US7962573B2 (en) 2000-03-21 2011-06-14 Intel Corporation Method and apparatus to determine broadcast content and scheduling in a broadcast system
US8108542B2 (en) 2000-03-21 2012-01-31 Intel Corporation Method and apparatus to determine broadcast content and scheduling in a broadcast system
US8839298B2 (en) 2000-03-21 2014-09-16 Intel Corporation Method and apparatus to determine broadcast content and scheduling in a broadcast system
US7167895B1 (en) 2000-03-22 2007-01-23 Intel Corporation Signaling method and apparatus to provide content on demand in a broadcast system
US7275254B1 (en) 2000-11-21 2007-09-25 Intel Corporation Method and apparatus for determining and displaying the service level of a digital television broadcast signal
US20020144265A1 (en) * 2001-03-29 2002-10-03 Connelly Jay H. System and method for merging streaming and stored content information in an electronic program guide
US20020144269A1 (en) * 2001-03-30 2002-10-03 Connelly Jay H. Apparatus and method for a dynamic electronic program guide enabling billing broadcast services per EPG line item
US20020167947A1 (en) * 2001-05-11 2002-11-14 Hallford Jason C. Method and apparatus for combining broadcast schedules and content on a digital broadcast-enabled client platform
US7185352B2 (en) 2001-05-11 2007-02-27 Intel Corporation Method and apparatus for combining broadcast schedules and content on a digital broadcast-enabled client platform
US20020194585A1 (en) * 2001-06-15 2002-12-19 Connelly Jay H. Methods and apparatus for providing ranking feedback for content in a broadcast system
US20020194607A1 (en) * 2001-06-15 2002-12-19 Connelly Jay H. Method and apparatus for periodically delivering an optimal batch broadcast schedule based on distributed client feedback
US20020194598A1 (en) * 2001-06-15 2002-12-19 Connelly Jay H. Method and apparatus for continuously and opportunistically driving an optimal broadcast schedule based on most recent client demand feedback from a distributed set of broadcast clients
US20020193066A1 (en) * 2001-06-15 2002-12-19 Connelly Jay H. Methods and apparatus for providing rating feedback for content in a broadcast system
US7020893B2 (en) 2001-06-15 2006-03-28 Intel Corporation Method and apparatus for continuously and opportunistically driving an optimal broadcast schedule based on most recent client demand feedback from a distributed set of broadcast clients
US7055165B2 (en) 2001-06-15 2006-05-30 Intel Corporation Method and apparatus for periodically delivering an optimal batch broadcast schedule based on distributed client feedback
US20030005301A1 (en) * 2001-06-28 2003-01-02 Jutzi Curtis E. Apparatus and method for enabling secure content decryption within a set-top box
US7328455B2 (en) 2001-06-28 2008-02-05 Intel Corporation Apparatus and method for enabling secure content decryption within a set-top box
US7363569B2 (en) 2001-06-29 2008-04-22 Intel Corporation Correcting for data losses with feedback and response
US20030016673A1 (en) * 2001-06-29 2003-01-23 Ramesh Pendakur Correcting for data losses with feedback and response
US8209574B2 (en) 2001-06-29 2012-06-26 Intel Corporation Correcting for data losses with feedback and response
US20050060752A1 (en) * 2001-06-29 2005-03-17 Intel Corporation Correcting for data losses with feedback and response
US7269775B2 (en) 2001-06-29 2007-09-11 Intel Corporation Correcting for data losses with feedback and response
US7047456B2 (en) 2001-08-28 2006-05-16 Intel Corporation Error correction for regional and dynamic factors in communications
US20030046708A1 (en) * 2001-08-28 2003-03-06 Jutzi Curtis E. Error correction for regional and dynamic factors in communications
US20030046683A1 (en) * 2001-08-28 2003-03-06 Jutzi Curtis E. Server-side preference prediction based on customer billing information to generate a broadcast schedule
US7231653B2 (en) 2001-09-24 2007-06-12 Intel Corporation Method for delivering transport stream data
US8943540B2 (en) 2001-09-28 2015-01-27 Intel Corporation Method and apparatus to provide a personalized channel
US20030109448A1 (en) * 2001-11-07 2003-06-12 Crowley Kathleen S. Methods of promoting uptake and nuclear accumulation of polyamides in eukaryotic cells
US20030135553A1 (en) * 2002-01-11 2003-07-17 Ramesh Pendakur Content-based caching and routing of content using subscription information from downstream nodes
US20030135605A1 (en) * 2002-01-11 2003-07-17 Ramesh Pendakur User rating feedback loop to modify virtual channel content and/or schedules
US20030135857A1 (en) * 2002-01-11 2003-07-17 Ramesh Pendakur Content discovery in a digital broadcast data service
US20140371164A1 (en) * 2011-12-20 2014-12-18 Ectin Research Ab Synergistic Combination Comprising Avermectins and a NSAID for Tumor Inhibition
US9782424B2 (en) * 2011-12-20 2017-10-10 Ectin Research Ab Synergistic combination comprising avermectins and a NSAID for tumor inhibition
WO2014152864A1 (fr) * 2013-03-14 2014-09-25 Panacea Pharmaceuticals Traitement d'un déficit cognitif induit par une chimiothérapie
CN112898224A (zh) * 2019-12-04 2021-06-04 中国科学院上海药物研究所 一种烯丙基醇支撑的大环内酯化合物及其用途
CN112898224B (zh) * 2019-12-04 2023-02-17 中国科学院上海药物研究所 一种烯丙基醇支撑的大环内酯化合物及其用途

Also Published As

Publication number Publication date
DE69832375T2 (de) 2006-06-01
EP0979089B1 (fr) 2005-11-16
AU744406B2 (en) 2002-02-21
DK0979089T3 (da) 2005-12-12
WO1998048813A1 (fr) 1998-11-05
NZ500429A (en) 2001-05-25
AU7073698A (en) 1998-11-24
ES2252832T3 (es) 2006-05-16
CA2289086A1 (fr) 1998-11-05
EP0979089A1 (fr) 2000-02-16
CA2289086C (fr) 2008-07-15
DE69832375D1 (de) 2005-12-22
ATE309805T1 (de) 2005-12-15

Similar Documents

Publication Publication Date Title
US6114376A (en) Methods for using macrocyclic lactone compounds as multidrug resistance reversing agents in tumor and other cells
Prichard et al. Moxidectin and the avermectins: consanguinity but not identity
CN104470941A (zh) 靶向治疗学
SI9520021A (en) Antiparasitic agents, compuonds related to the avermectins and milbemycins but having substituents at the 3-position
SA98190435A (ar) 4- أمينوبيرول (3،2-d) بيريميدينات كمضادات لمستقبل الببتيد العصبي y .
US20160184340A1 (en) The use of spinosyns and spinosyn compositions as local anesthetics and as antiarrhythmic agents
Liang et al. Multidrug transporters as drug targets
CA2659537C (fr) Procedes et compositions destines a favoriser l'effet de therapies anti-cancer
US6420377B1 (en) Covalent conjugates of topoisomerase I and topoisomerase II inhibitors
US20020032161A1 (en) Cyclodextrin compositions
Meinke Perspectives in animal health: old targets and new opportunities
Lafi et al. A review Echinomycin: a journey of challenges
Monshouwer et al. Selective effects of a bacterial infection (Actinobacillus pleuropneumoniae) on the hepatic clearances of caffeine, antipyrine, paracetamol, and indocyanine green in the pig
US20210261594A1 (en) Use of avermectin derivative for increasing bioavailability and efficacy of macrocylic lactones
AU2011268899C1 (en) Injectable formulation of a macrocyclic lactone and levamisole
Rock et al. Chemistry, pharmacology and safety: moxidectin
JP2003511396A (ja) 化学療法を増強する方法
Jung et al. Chemistry, pharmacology and safety: milbemycin oxime
Joint et al. Residues of some veterinary drugs in animals and foods
Elazab et al. Effects of verapamil on the pharmacokinetics of ivermectin in rabbits
MXPA99009997A (en) Methods for using macrocyclic lactone compounds as multidrug resistance reversing agents in tumor and other cells
Rox et al. Pharmacokinetic and pharmacodynamic evaluation of the atypical tetracyclines chelocardin and amidochelocardin in murine infection models
EP3595441B1 (fr) Composition veterinaire topique stable
SK88598A3 (en) Macrocyclic compounds made from suboxide units
Schaeffer et al. Avermectins: Idiosyncratic toxicity in a subpopulation of collie dogs

Legal Events

Date Code Title Description
AS Assignment

Owner name: INTERNATIONAL BUSINESS MACHINES CORPORATION, NEW Y

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BAYARDO, ROBERTO J.;REEL/FRAME:009139/0586

Effective date: 19980429

AS Assignment

Owner name: MCGILL UNIVERSITY, CANADA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PRICHARD, ROGER K.;POULIOT, JEAN-FRANCOIS;GEORGES, ELIAS;REEL/FRAME:010946/0229;SIGNING DATES FROM 20000512 TO 20000516

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

REMI Maintenance fee reminder mailed
FPAY Fee payment

Year of fee payment: 4

SULP Surcharge for late payment
FPAY Fee payment

Year of fee payment: 8

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20120905

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载